Paraoxonase 1-192Q allele is a risk factor for idiopathic chronic pancreatitis

Molecular Diagnosis

Volumn 9, Issue 1, 2005, Pages 9-15

  Verlaan, Mariette ^a   Harbers, Erik G A ^a   Pap, Akos ^b   Jansen, Jan B M J ^a   Peters, Wilbert H M ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAV Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; DNA; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE;

ADULT; AGED; ALCOHOLIC PANCREATITIS; ALCOHOLISM; ALLELE; ARTICLE; CAUCASIAN; CHRONIC PANCREATITIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SAMPLING; CHRONIC DISEASE; ENZYMOLOGY; GENE FREQUENCY; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; ALLELES; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CHRONIC DISEASE; FEMALE; GENE FREQUENCY; HUMANS; MALE; MIDDLE AGED; PANCREATITIS; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS;

EID: 26944434865     PISSN: 10848592     EISSN: 10848592     Source Type: Journal    
DOI: 10.2165/00066982-200509010-00002     Document Type: Article

References (46)

1. Witt H, Luck W, Hennies HC, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000 Jun; 25 (2): 213-6
2. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001 Feb; 120 (3): 682-707
3. Drenth JP, te Morsche R, Jansen JB. Mutations in serine protease inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. Gut 2002 May; 50 (5): 687-92
4. Jansen JB, te Morsche R, van Goor H, et al. Genetic basis of chronic pancreatitis. Scand J Gastroenterol 2002; 37 Suppl. 236: 91-4
5. Steer ML, Waxman I, Freedman S. Chronic pancreatitis. N Engl J Med 1995 Jun; 332 (22): 1482-90
6. Bulger EM, Helton WS. Nutrient antioxidants in gastrointestinal diseases. Gas toenterol Clin North Am 1998 Jun; 27 (2): 403-19
7. Schoenberg MH, Birk D, Beger HG. Oxidative stress in acute and chronic pancreatitis. Am J Clin Nutr 1995 Dec; 62 (6 Suppl.): 1306S-14S
8. Ulrich AB, Schmied BM, Matsuzaki H, et al. Increased expression of glutathione S-transferase-pi in the islets of patients with primary chronic pancreatitis but not secondary chronic pancreatitis. Pancreas 2001 May; 22 (4): 388-94
9. Santini SA, Spada C, Bononi F, et al. Liver, Pancreas and biliary tract enhanced lipoperoxidation products in pure pancreatic juice: evidence for organ-specific oxidative stress in chronic pancreatitis. Dig Liver Dis 2003 Dec; 35 (12): 888-92
10. Seicean A, Grigorescu M. The pathogenesis of chronic alcoholic pancreatitis. Rom J Gastroenterol 2002 Mar; 11 (1): 19-24
11. Matsumura N, Ochi K, Ichimura M, et al. Study on free radicals and pancreatic fibrosis-pancreatic fibrosis induced by repeated injections of superoxide dismutase inhibitor. Pancreas 2001 Jan; 22 (1): 53-7
12. Mathew P, Wyllie R, Van Lente F, et al. Antioxidants in hereditary pancreatitis. Am J Gastroenterol 1996 Aug; 91 (8): 1558-62
13. Wallig MA. Xenobiotic metabolism, oxidant stress and chronic pancreatitis: focus on glutathione. Digestion 1998; 59 Suppl. 4: 13-24
14. Hegele RA. Paraoxonase genes and diseases. Ann Med 1999 Jun; 31 (3): 217-24
15. Draganov DI, La Du BN, Pharmacogenetics of paraoxonases: a brief review. Naunyn-Schmiedebergs Arch Pharmacol 2003 Jan; 369 (1): 78-88
16. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density protein. J Clin Invest 1995 Dec; 96 (6): 2882-91
17. Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993 Jan; 3 (1): 73-6
18. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998 Sep; 31 (3): 329-36
19. Leviev I, Negro F, James RW. Two alleles of the human paraoxogenase gene produce different amounts of mRNA: an explanation for differences in serum concentrations of paraoxogenase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997 Nov; 17 (11): 2935-9
20. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovasculair disease in diabetes. J Clin Invest 1997 Jan; 99 (1): 62-6
21. Mackness B, Mackness MI, Arrol S, et al. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997 Sep; 122 (2): 265-8
22. Aviram M, Billecke S, Sorenson R. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998 Oct; 18 (10): 1617-25
23. Oliveira SA, Mansur AP, Ribeiro CC, et al. PON1 M/L55 mutation protects high-risk patients against coronary artery disease. Int J Cardiol 2004 Mar; 94 (1): 73-7
24. Shih DM, Gu L, Xia YR. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998 Jul; 394 (6690): 284-7
25. Kuremoto K, Watanabe Y, Ohmura H, et al. R/R genotype of human paraoxonase (PON1) is more protective against lipoprotein oxidation and coronary artery disease in Japanese subjects. J Artheroscler Thromb 2003; 10 (2): 85-92
26. Kaestner KH, Lee CS, Scearce LM, et al. Transcriptional program of the endocrine pancreas in mice and humans. Diabetes 2003 Jul; 52 (7): 1604-10
27. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996 Apr; 7 (2): 69-76
28. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995 Jun; 115 (2): 243-53
29. Mackness MI, Arrol S, Abbott C, et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993 Dec; 104 (1-2): 129-35
30. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 1991 Aug; 286 (3): 152-4
31. Hayek T, Oiknine J, Dankner G, et al. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: studies in transgenic mice. Eur J Chem Clin Biochem 1995 Oct; 33 (10): 721-5
32. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000 May; 101 (21): 2510-7
33. Foster JR, Idle JR, Hardwick JP, et al. Induction of drug-metabolizing enzymes in human pancreatic cancer and chronic pancreatitis. J Pathol 1993 Apr; 169 (4): 457-63
34. Wacke R, Kirchner A, Prall F, et al. Up-regulation of cytochrome P450 1A2, 2C9 and 2E1 in chronic pancreatitis. Pancreas 1998 May; 16 (4): 521-8
35. Brophy VH, Jarvik GP, Furlong CE. PON1 polymorphisms. 2002. In: Costa LG, Furlong CE, editors. Paraoxonase (PON1) in health and diseases. Kluwer, Norwell, Boston (MS), 2002: 53-78
36. Ruiz J, Blanche H, James RW, et al. Gl-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995 Sep; 346 (8979): 869-72
37. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995 Dec; 96 (6): 3005-8
38. Sanghera DK, Saha N, Aston CE, et al. Genetic polymorphisms of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997 Jun; 17 (6): 1067-73
39. Voetsch B, Benke KS, Damasceno BP, et al. Paraoxonase 192 Gln →Arg polymor-phism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 2002 Jun; 33 (6): 1459-64
40. Herrmann SM, Blanc H, Poirier O, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996 Oct; 126 (2): 299-303
41. Antikainen M, Murtomaki S, Syvanne M, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996 Aug; 98 (4): 883-5
42. Rice GI, Ossei-Gerning N, Stickland MH, et al. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischemic heart disease. Coron Artery Dis 1997 Nov-Dec; 8 (11-12): 677-82
43. Ombres D, Pannitteri G, Montali A, et al. The Gl-Arg 192 polymorphism of human paraoxonase gene is not associated with coronary disease in Italian patients. Arterioscler Thromb Vasc Biol 1998 Oct; 18 (10): 1611-6
44. Davies HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996 Nov; 14 (3): 334-6
45. Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000 Nov; 28 (11): 1335-42
46. Brophy VH, Jarvik GP, Richter RJ, et al. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype. Pharmacogenetics 2002 Jul; 10 (5): 453-60